Gain-of-function mutation of the K-ras gene is one of the most common genetic changes in human tumors. In tumors carrying K-ras mutation, the presence of oncogenic K-Ras is necessary for maintenance of the transformed phenotype. ESXR1 is a human paired-like homeodomain-containing protein expressed primarily in the testis. In cells, the 65-kDa full-length ESXR1 protein is proteolytically processed into an N-terminal 45-kDa fragment containing the homeodomain, which localizes exclusively within the nucleus, and a C-terminal 20-kDa fragment consisting of a proline-rich repeat region, which is located in the cytoplasm. In this work, we demonstrated that the N-terminal ESXR1 fragment specifically recognizes the TAATNNNATTA P3 consensus sequence for the paired-like homeodomain and functions as a sequencespecific transcriptional repressor. We also showed that the N-terminal ESXR1 fragment binds to the TAATGTTAT TA sequence present within the first intron of the human K-ras gene and inhibits its expression at both mRNA and protein levels. Ectopic expression of the N-terminal ESXR1 fragment in human carcinoma cells that carry mutated K-ras reduces the level of K-Ras and thereby inhibits the tumor cell proliferation. Identification of ESXR1 as a transcriptional repressor of K-ras has an important implication for the development of cancer therapy that inhibits oncogenic K-Ras expression.
Introduction
Mutation in ras oncogenes is one of the most common genetic changes associated with human tumors (Bos, 1989) . In mammalian cells, there are three functional ras genes, H-ras, K-ras and N-ras, that encode highly homologous 21-kDa proteins. These Ras proteins are located on the inner surface of the plasma membrane and act as molecular switches that convey mitogenic signals from the cell surface to the nucleus. Ras is in the active form when bound to GTP and in the inactive form when bound to GDP. Point mutations at codons 12, 13 and 61 of Ras impair its ability to hydrolyse GTP to GDP, so that Ras is maintained in its active state. Gain-of-function mutations in ras genes are present in about 30% of all human cancers, with K-ras mutations occurring most frequently (Forrester et al., 1987; Rodenhuis et al., 1987; Hruban et al., 1993) . In addition to activation by point mutations, K-ras has been found to be amplified or overexpressed in some cancers (Galiana et al., 1995) . Studies using genetically engineered mice have shown that the presence of oncogenic K-ras is not only essential for the initiation of tumorigenesis but also necessary for maintenance of the transformed state (Fisher et al., 2001; Johnson et al., 2001; Meuwissen et al., 2001) . Thus, K-Ras is a crucial molecular target in therapeutic strategies to inhibit tumor cell growth. Indeed, several techniques, such as techniques using farnesyl-transferase inhibitors, antisense oligonucleotides or siRNAs, have been developed to inhibit the activity of oncogenic K-Ras (Adjei, 2001; Andreyev et al., 2001; Brummelkamp et al., 2002) . However, because of its nature as a housekeeping gene, little attention has been focused on the transcriptional control of K-ras in the context of cancer therapy.
ESXR1 was cloned on the basis of its sequence homology with a mouse paired-like homeobox gene, Esx1/SPX1 (Fohn and Behringer, 2001 ). Independently, we also isolated the same gene as a human cDNA that can rescue yeast cells from toxicity caused by human cyclin (Ozawa et al., 2004) . ESXR1 encodes a human paired-like homeodomain-containing protein, ESXR1. The homeodomain of ESXR1 exhibits 65% identity with that of mouse Esx1/SPX1. Outside the homeodomain, however, ESXR1 has no significant sequence homology with Esx1/SPX1. Thus, it is not clear whether ESXR1 is a human orthologue of mouse Esx1/SPX1. ESXR1 is primarily expressed in the testis in adult human tissues. In the cell, the full-length 65-kDa ESXR1 protein is proteolytically cleaved into an Nterminal 45-kDa fragment that contains a homeodomain and a C-terminal 20-kDa fragment that possesses a proline-rich repeat sequence. We have shown that the full-length ESXR1 and the C-terminal fragment localize to the cytoplasm and inhibit degradation of mitotic cyclins, thereby inducing M-phase cell-cycle arrest (Ozawa et al., 2004) , whereas the N-terminal fragment is localized exclusively within the nucleus, indicating its role in transcription as in the case of many other homeoproteins (Levine and Hoey, 1988; Wilson et al., 1993; Gehring et al., 1994) .
In this work, we demonstrated that the N-terminal ESXR1 fragment, which contains the homeodomain, acts as a sequence-specific transcriptional repressor for the human K-ras gene. We also showed that the N-terminal ESXR1 fragment inhibits growth of cancer cells harboring oncogenic K-ras. Our results provide important information for the development of a method of cancer treatment that targets oncogenic K-ras by ESXR1.
Results

Sequence-specific transcriptional repressor activity of ESXR1
Since ESXR1 possesses a paired-like homeodomain, we investigated the potential role of ESXR1 in transcription. We first examined if the ESXR1 homeodomain possesses a specific DNA-binding activity. Cyclic amplification and selection of targets (CASTing) (Wright et al., 1991) using the palindromic P3 consensus sequence for the paired-like homeodomain (Wilson et al., 1993) , 5 0 -TAATNNNATTA-3 0 (where N designates A, T, G or C), and the affinity-purified GST-ESXR1 homeodomain fusion protein revealed that ESXR1 binds specifically to the P3 sequence ( Figure 1a ). To confirm specific binding of ESXR1 to the P3 sequence, we next performed an electrophoretic mobility shift assay (EMSA) using 32 P-labeled doublestranded oligonucleotides containing a 3 Â (TAATTT GATTA) consensus sequence and cell lysates prepared from COS-7 cells expressing N-terminal Myc epitopetagged, wild-type ESXR1 (WT-ESXR1) (Figure 1b, left) . Several slow migrating bands representing protein-DNA complexes were observed. Among these, three bands (marked by arrows) were competed out by excess of the unlabeled oligonucleotides (lanes 8, 9, 10), but not by the unlabeled mutant oligonucleotides (lanes 11, 12). These three bands were also supershifted by an anti-ESXR1 antibody (lane 7). The results confirm that ESXR1 is capable of binding specifically to the P3 consensus sequence.
In adult human tissues, ESXR1 mRNA is primarily expressed in the testis (Fohn and Behringer, 2001; Ozawa et al., 2004) . Consistent with this, ESXR1 is expressed in testicular germ cell tumors, where a fraction of the 65-kDa full-length ESXR1 protein is processed into N-terminal 45-kDa and C-terminal 20-kDa fragments. We have previously shown that the full-length ESXR1 protein and the C-terminal fragment are localized to the cytoplasm, whereas the N-terminal fragment is located only in the nucleus (Ozawa et al., 2004) . Given this, we next investigated whether the Nterminal fragment is responsible for the DNA-binding activity of ESXR1. To do so, we employed a C-terminal deletion mutant of ESXR1, ESXR1-DC, which corresponds in both structure and size to the N-terminal 45-kDa fragment of ESXR1 (Ozawa et al., 2004) . The N-terminal Myc-tagged ESXR1-DC was expressed in COS-7 cells. EMSA using COS-7 cell lysates and P3 consensus oligonucleotides revealed specific protein-DNA complex bands, which were again supershifted by an anti-ESXR1 antibody (Figure 1b, right) . Hence, the N-terminal 45-kDa fragment is sufficient for binding of ESXR1 to the consensus DNA sequence. Next, to investigate the functional consequence of the ESXR1-DNA interaction, we performed a luciferase reporter assay using the pGL3-Promoter vector, which contains a simian virus 40 (SV40) early promoter upstream of the luciferase gene. Three copies of the P3 consensus sequence (TAATTTGATTA) were inserted upstream of the SV40 promoter in the pGL3-Promoter. The resulting reporter construct was transfected into U2-OS human osteosarcoma cells together with the WT-ESXR1 expression vector and the internal control pRL-TK. Luciferase activities were normalized with the dual-luciferase system. As shown in Figure 1c (left), WT-ESXR1 significantly repressed activity of the SV40 promoter that was connected to the P3 consensus sequences. On the other hand, WT-ESXR1 had little effect on activity of the SV40 promoter without the P3 consensus sequence (Figure 1c, right) . Thus, ESXR1 is capable of repressing heterologous promoter activity upon specific binding to a nearby cis-element. Given that full-length ESXR1 is proteolytically cleaved into Nand C-terminal fragments in cells, the N-terminal fragment may actually function as a transcriptional repressor in the reporter assay.
K-ras as a target gene of ESXR1
To elucidate the physiological role of ESXR1 as a transcriptional repressor, we next investigated target genes of ESXR1 by utilizing the U2-OS human osteosarcoma-derived cell line U2/tetESXR1, which inducibly expresses Myc-tagged WT-ESXR1 in a doxycycline (DOX)-dependent manner (Ozawa et al., 2004) . In this regard, constitutive expression of fulllength ESXR1 causes M-phase cell-cycle arrest in U2-OS cells (Ozawa et al., 2004) , which may also affect gene expression. Since we wished to investigate the direct effect of ESXR1 on transcription without considering its effect on the cell cycle, we performed a kinetic study of ESXR1 induction in U2/tetESXR1 cells and found that the cells inducibly express sufficient levels of ESXR1 but do not show any cell cycle alteration at 12 h after the addition of DOX (data not shown). Accordingly, total RNAs were extracted from U2/tetESXR1 cells cultured in the presence or absence of DOX for 12 h and were subjected to a DNA microarray analysis. As a control, RNAs were extracted from parental U2-OS-derived Tet-on cells treated with DOX for 12 h or not treated.
Since ESXR1 exhibited a sequence-specific transcriptional repressor activity in the luciferase reporter assay, we focused on genes of which expression was repressed more than 0.8 (log 2 ratio) by ESXR1 induction and identified K-ras as one such gene (Table 1 ). The K-ras promoter lacks an obvious TATA or CCAAT box, with Figure 1 Sequence-specific transcriptional repressor activity of ESXR1. (a) ESXR1 homeodomain binds TAATNNNATTA sequence. CASTing was performed using the P3 consensus binding sequence for the paired-like homeodomain, TAATNNNATTA, and GST or GST-fused ESXR1 homeodomain (GST-ESXR1-HD). PCR-amplified products were run on DNA agarose gel (left). Consensogram of sequences selected by the homeodomain of ESXR1 (right). (b) Specific ESXR1-DNA complex. EMSA was performed using a 3 Â (TAATTTGATTA) P3-consensus probe and lysates from cells transfected with WT-ESXR1, ESXR1-DC or control empty vector Three Â (TACTTTGAGGC) P3-mutant probe (MT) was used as a non-specific competitor. Arrows represent sequence-specific ESXR1-DNA complexes. (c) Suppression of heterologous promoter by ESXR1. pGL3-Promoter (right) or pGL3-Promoter containing 3 Â (TAATTTGATTA) sequence (left) was transfected into U2-OS cells along with WT-ESXR1 expression vector or control empty vector. Cell lysates were subjected to luciferase assay. Bars represent 2 Â s.d. of the three independent experiments Transcriptional repression of K-ras by ESXR1
M Yanagihara et al multiple transcription start sites, and is therefore classified as a housekeeping gene ubiquitously expressed in somatic cells (Hoffman et al., 1987; Jordano and Perucho, 1988) . Intriguingly, however, the level of K-ras mRNA changes dramatically during spermatogenesis of male germ cells, in which ESXR1 is most abundantly expressed (Wolfes et al., 1989) . If K-ras is a bona fide target gene of ESXR1 as suggested by the results of the microarray analysis, then ectopic expression of ESXR1 in cells that lack ESXR1 expression should downregulate endogenous K-Ras expression. Accordingly, we investigated the levels of K-Ras before and after ESXR1 induction for 12 h by DOX in U2/tetESXR1 cells. Anti-K-Ras immunoblotting revealed a significant decrease in the level of K-Ras upon ESXR1 expression ( Figure 2a ). As mentioned above, induction of ESXR1 for 12 h by DOX did not affect the cell-cycle distribution of U2/tetESXR1 cells, arguing against the idea that reduced K-Ras is due to the cell-cycle effect of ESXR1. Indeed, the level of K-Ras was not altered in cells arrested at S or M phase ( Figure 2b ). Accordingly, K-Ras expression is independent of the cell cycle. The effect of ESXR1 on Ras was specific to K-Ras because ESXR1 did not affect the level of H-Ras, another member of the Ras family ( Figure 2c ). Inhibition of K-Ras expression was also observed when ESXR1-DC, which lacks the C-terminal repeat region, was inducibly expressed in a U2-OS-derived stable transfectant, U2/tetDC ( Figure 2d ). Hence, the ability of ESXR1 to inhibit K-ras is mediated by the N-terminal region, which contains the homeodomain, but is totally independent of the C-terminal repeat region, which is responsible for M-phase arrest.
To confirm that downregulation of K-Ras by ESXR1 occurs at the transcriptional level, we performed a realtime PCR analysis and concluded that both WT-ESXR1 and ESXR1-DC reduce K-ras mRNA level ( Figure 3 ).
Repressor cis-element of K-ras gene targeted by ESXR1
To elucidate the mechanism by which ESXR1 inhibits K-ras, we searched the genomic sequence of the human K-ras gene and found a P3 consensus sequence (TAATGTTATTA) within the first intron of the gene ( Figure 4a ). To determine whether the identified sequence can function as a repressor cis-element of K-ras, a 51-bp genomic fragment that contains the TAATGTTATTA sequence was synthesized and inserted into the pGL3-Promoter vector. Co-transfection of the reporter plasmid together with WT-ESXR1 resulted in a reduction in the luciferase activity ( Figure 4b , left). On the other hand, introduction of mutations into the consensus sequence within the 51-bp nucleotide, from TAATGTTATTA to TACTGTTAGGC, abolished the repressor activity of ESXR1 ( Figure 4b , Among genes transcriptionally repressed more than 0.8 (log 2 ratio) upon 12 h induction of ESXR1 by DOX in U2/tetESXR1 cells, those that possess the palindromic P3 consensus binding sequence, TAATNNNATTA, in their genome sequences are shown. The change in expression level is indicated as log 2 ratio of the fold change vs the expression level of uninducible cell
The results indicate that the TAATGTTATTA sequence within the first intron of the K-ras gene functions as a repressor cis-element, to which ESXR1 binds and suppresses K-ras mRNA transcription. This conclusion was further supported by results of EMSA demonstrating that both WT-ESXR1 and ESXR1-DC bound to the 51-bp oligonucleotides but not to the mutant oligonucleotides (Figure 4c ). Accordingly, we designated the intronic TAATGTTATTA sequence 'repressor element of K-ras (REK)'. To determine whether ESXR1 indeed binds to REK within the cell, we performed a chromatin immunoprecipitation (CHIP) experiment. U2/tetESXR1 or U2/tetDC cells were treated with DOX for 12 h to induce Myc-tagged WT-ESXR1 or ESXR1-DC. The cells were then treated with formaldehyde, and cell lysates prepared were immunoprecipitated with anti-TFIIB, anti-Myc, anti-ESXR1, or control IgG. The immunoprecipitates were subjected to PCR with respective primer sets. A 249-bp fragment corresponding to the first intron sequence containing REK was specifically amplified from the anti-Myc or anti-ESXR1 immunoprecipitates (Figure 4d ). In cells expressing WT-ESXR1, the N-terminal ESXR1 fragment, which is generated from full-length WT-ESXR1 through proteolysis, may directly bind to REK within the cell.
Growth inhibition of tumor cells carrying oncogenic K-ras by ESXR1
Constitutive expression of oncogenic K-Ras is required for maintenance of the transformed phenotype of cancer cells carrying K-ras mutation (Adjei, 2001; Andreyev et al., 2001; Fisher et al., 2001; Brummelkamp et al., 2002) . Accordingly, we next investigated the effect of ESXR1-DC on the growth of tumor cells carrying wildtype or oncogenic K-ras. SW480 human colon carcinoma cells possess oncogenic K-ras, whereas U2-OS human osteosarcoma cells have wild-type K-ras. The ESXR1-DC expression vector was stably transfected into SW480 cells or U2-OS cells. After selection of transfected cells with puromycin, drug-resistant colonies were expanded and expression of ESXR1-DC in ESXR1-DC transfectants was determined by anti-ESXR1-DC immunoblotting. Cells from ESXR1-DC-positive and ESXR1-DCnegative colonies were subjected to further analysis. As Transcriptional repression of K-ras by ESXR1 M Yanagihara et al shown in Figure 5a , expression of K-Ras was significantly reduced in SW480 cells expressing ESXR1-DC (left) and was hardly detectable in U2-OS cells expressing ESXR1-DC (right). Upon growth curve analysis, ESXR1-DC-positive SW480 cells exhibited a reduced growth rate compared with the growth rate of ESXR1-DC-negative SW480 cells. On the other hand, there was no difference between the growth rates of ESXR1-DCpositive and -negative U2-OS cells. The results indicate that ESXR1-DC inhibits growth of SW480 cells but not that of U2-OS cells. The growth-inhibitory activity of ESXR1-DC on SW480 cells explains why we could only obtain SW480 stable transfectants that express low levels of ESXR1-DC, which result in moderately reduced levels of K-Ras. Furthermore, we were not able to expand ESXR1-DC-positive SW480 cells from a single cell by the limiting dilution method. The results also indicate that even a moderate reduction of the K-Ras level (B2-fold) can significantly inhibit the growth of tumor cells with K-ras mutation.
To determine whether the growth-inhibitory effect of ESXR1-DC on SW480 cells was due to downregulation of oncogenic K-ras expression, we next performed a colony formation-suppression assay. SW480 cells were co-transfected with a puromycin-resistance gene and ESXR1-DC, ESXR1-DC þ K-Ras val12 , or control empty vector. Transfected cells were then selected by puromycin. Formation of puromycin-resistant colonies was strongly inhibited in cells co-transfected with ESXR1-DC. The suppression of colony formation by ESXR1-DC was overcome by co-expressing K-Ras val12 ( Figure 6a ). The results of the add-back experiment provide strong evidence that growth inhibition of SW480 cells by ESXR1-DC is due to repression of Kras and not due to some other ESXR1-regulated genes.
To substantiate the conclusion that ESXR1-DC inhibits growth of tumor cells carrying the oncogenic K-ras gene, we examined the effect of ESXR1-DC on other tumor cells by the colony formation-suppression assay. HCT116 human colon carcinoma cells and AGS gastric carcinoma cells possess the oncogenic K-ras gene, whereas MKN28 human gastric carcinoma cells have wild-type K-ras gene. Cells were co-transfected with a puromycin-resistance gene and ESXR1-DC expression vector or control empty vector, and were selected by puromycin. ESXR1-DC potently inhibited formation of 
Discussion
In the present work, we investigated the role of human paired-like homeobox-containing protein ESXR1 in transcription and found that ESXR1 specifically binds to the TAATNNNATTA sequence through the homeodomain and represses transcription. We also found that human K-ras is one of the ESXR1 target genes and provided evidence that ESXR1 represses K-ras transcription by specifically binding to the TAATGTTAT TA sequence present within the first intron of the human K-ras gene. Growth of tumor cells having oncogenic K-ras was strongly inhibited through downregulation of K-Ras by ESXR1.
In cells, the ESXR1 protein is present in three distinct forms as a result of proteolytic processing: 65-kDa fulllength protein and 45-kDa N-terminal and 20-kDa C-terminal fragments (Ozawa et al., 2004) . We have reported that the 65-kDa full-length protein as well as the C-terminal fragment, both of which are localized to the cytoplasm, are potent inhibitors of the cell cycle, arresting cells in the M-phase by preventing degradation of mitotic cyclins. On the other hand, the 45-kDa N-terminal fragment, which contains the homeodomain, is exclusively localized to the nucleus (Ozawa et al., 2004) . We demonstrated in this work that the Nterminal ESXR1 fragment, which is generated from the full-length ESXR1 in the cells and specifically localizes to the nucleus, acts as a sequence-specific transcriptional repressor. These findings collectively indicate that proteolytic processing of ESXR1 generates two peptide fragments, which exert distinct functional activities in different intracellular compartments, and suggest an important role of proteolysis in coordinating distinct biological processes in both spatial and temporal fashions.
In adult human tissues, ESXR1 mRNA is specifically detectable in the testis, suggesting that ESXR1 plays a role in spermatogenesis (Fohn and Behringer, 2001; Ozawa et al., 2004) . K-Ras is expressed ubiquitously in mouse embryos, fetuses, placentas, and extraembryonic tissues as well as postnatal tissues, but its expression changes dramatically during spermatogenesis (Wolfes et al., 1989) . The level of K-ras mRNA is very low in male germ cells before preleptotene phase, but becomes high in the cells during preleptotene and pachytene phases. Our present work raises an intriguing possibility that ESXR1 is responsible for the dynamic changes in K-ras mRNA levels observed during spermatogenesis. ESXR1 may inhibit progression of meiosis I by inducing M-phase arrest through its C-terminal fragment, while its N-terminal fragment may regulate expression of genes involved in stage-specific differentiation of male germ cells. Downregulation of ESXR1 expression might trigger entry to and progression of meiosis I through induction of K-ras and other growth-controlling genes involved in meiosis. Obviously, the physiological role of ESXR1-K-ras interplay during spermatogenesis needs further investigation.
Oncogenic mutation in the K-ras gene is one of the most frequent genetic changes in human cancer. K-ras mutation has been detected in 70-90% of pancreatic carcinomas, 50% of colorectal carcinomas, and 20-50% of lung carcinomas (Forrester et al., 1987; Rodenhuis et al., 1987; Bos, 1989; Hruban et al., 1993) . In tumor cells carrying K-ras mutation, the presence of oncogenic K-Ras is necessary for maintenance of the transformed phenotype (Fisher et al., 2001; Johnson et al., 2001; Meuwissen et al., 2001) . Given this, several techniques, such as techniques using farnesyl-transferase inhibitors, antisense oligonucleotides, ribozymes or siRNAs, have been developed to inhibit the activity of Ras (Adjei, 2001; Andreyev et al., 2001; Brummelkamp et al., 2002) . Our work provides an additional molecular tool to inhibit oncogenic K-Ras. Indeed, we demonstrated that downregulation of K-Ras by ectopic expression of the N-terminal ESXR1 fragment, ESXR1-DC, results in the inhibition of cancer cell proliferation. Although K-ras is an essential gene in mouse development and K-ras À/À embryos die between 12 and 14 days of gestation, with fetal liver defects and anemia, the growth and differentiation of other tissues proceed in an apparently normal manner in the absence of K-ras (Johnson et al., 1997) . Furthermore, the finding of a significant contribution by a K-ras À/À ES cell clone in tissues of In the absence of a system that specifically delivers a gene or a protein to cancer cells, a limited effect of K-Ras inhibition on normal cells may be advantageous when considering application of ESXR1 in cancer therapy. Since ESXR1 is primarily expressed in the testis, it may normally regulate K-ras only in limited cell types such as male germ cells. ESXR1 is located at human Xq22.1-22.3 (Ozawa et al., 2004) , and chromosomal abnormalities at Xq22 have been reported in male germ cell tumors (Summersgill et al., 2001; McIntyre et al., 2004) . Accordingly, the potential role of ESXR1 as a tumor suppressor gene needs to be extensively investigated in the near future. Nevertheless, a significant finding in the present work is the apparent capacity of ESXR1 as a sequence-specific transcriptional repressor for the K-ras gene. Obviously, our results suggest a potential application of ESXR1 for cancer therapy that targets oncogenic K-Ras.
Materials and methods
Plasmids
pcDNA3/WT-Myc-ESXR1 and pcDNA3/Myc-ESXR1-DC have been described previously (Ozawa et al., 2004) . A cDNA Cells U2-OS human osteosarcoma cells and COS-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Nissui PharmaCeutical Co., Tokyo, Japan) containing 10% fetal bovine serum (FBS). SW480 human colon carcinoma cells and HCT116 human colon carcinoma cells were cultured in DMEM/F12 (Invitrogen, Carlsbad, CA, USA) containing 10% FBS. MKN28 human gastric carcinoma cells and AGS human gastric carcinoma cells were cultured in RPMI 1640 medium (Nissui PharmaCeutical Co.) containing 10% FBS. U2/tetDC, which inducibly expresses Myc-tagged ESXR1-DC, was established by transfecting pOPTET-BSD/Myc-ESXR1-DC into U2-OS-derived Tet-on cells (Clontech Laboratories, Palo Alto, CA, USA) by the calcium phosphate precipitation method as described previously (Ozawa et al., 2004) . SW480-derived stable transfectants that constitutively express ESXR1-DC were established by co-transfecting pcDNA3/ Myc-ESXR1-DC and pBabe-puro vector into SW480 cells by the calcium phosphate precipitation method. Transfected cells were selected by 1.5 mg/ml puromycin. For colony formationsuppression assay, SW480, HCT116, MKN28, and AGS cells were transfected with 1 mg of pBabe-puro together with 10 mg ESXR1-DC expression vector and 10 mg K-Ras Val12 expression vector or 10 mg control vector. Transfected cells were selected by puromycin for 3 weeks and the drug-resistant colonies were stained with May-Giemsa reagent (Merck, Darmstadt, Germany).
Antibodies
Antibodies to K-Ras, actin, H-Ras, and HA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody for Myc was monoclonal antibody, 9E10. Anti-ESXR1 antiserum was raised by immunizing rabbits with a synthetic peptide (MESLRGYTHSDIGYRSL) corresponding to the N-terminal ESXR1 residues 1-17 (Ozawa et al., 2004) .
Cyclic amplification and selection of targets (CASTing)
CASTing was performed as described previously (Wright et al., 1991) . Amplification products were analysed by agarose gel electrophoresis. In all, 10 ml of the amplified material was used to initiate a second round of CASTing. Following eight cycles of CASTing, the amplified DNA was digested with BamHI and XbaI and then cloned into pBluescript vector, and the sequences of individual inserts were determined.
Microarray analysis
Details of microarray analysis in the MIAME compliant manner were deposited in the database of Research Center for Advanced Science and Technology, The University of Tokyo (http://www2.genome.rcast.u-tokyo.ac.jp/U2OS/index.html).
Briefly, total RNAs were extracted from U2/tetESXR1 cells or U2/tet parental cells cultured with or without DOX for 12 h using Trizol Reagent (GIBCO BRL, Gaithersburg, MD, USA) and were processed according to the protocol recommended by Affymetrix. In all, 5 mg of labeled cRNA from each sample was hybridized to the human genome U133A Plus 2.0 Array GeneChip (Affymetrix, Santa Clara, CA, USA) representing approximately 38 500 genes. The data output of GeneChip was normalized and analysed using Affymetrix GeneChip Operating Software ver1.1. The raw GeneChip data were transformed into log format following the recommendation by Affymetrix (Knudsen, 2002) .
Immunoblot analysis
Cells were lysed as described previously (Ashizawa et al., 2001) . The cell lysates (150 mg of proteins) were subjected to 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinylidene difluoride filters (Millipore Corp., Bedford, MA, USA), and immunoblotted with indicated antibodies. Proteins were visualized using the ECL detection system (Perkin-Elmer Life Sciences, Boston, MA, USA). For cell-cycle arrest, cells were treated with 5 mM hydroxyurea or 50 mM nocodazole for 12 h.
Flow cytometric analysis
Cells were fixed with 0.04% digitonin in buffer A (50 mM HEPES pH 7.2, 160 mM NaCl, 0.4% EGTA) on ice for 5 min. The cells were then incubated with 10 mg/ml propidium iodide (PI) and 100 mg/ml of RNase A on ice for 30 min. The intensity of PI staining was measured by FACS Caliber (Becton Dickinson, San Jose, CA, USA). Cell-cycle profiles were determined by use of the CELL Quest and ModFit cell-cycle analysis software (Becton Dickinson).
Luciferase reporter assay
In all, 2 mg of luciferase reporter plasmid and 0.1 mg of internal control pRL-TK (Promega) were transfected into U2-OS cells together with 20 mg of pcDNA3/WT-Myc-ESXR1 or pcDNA3 empty vector by the calcium phosphate precipitation method. At 12 h post-transfection, the cells were harvested and luciferase activities were measured using the dual luciferase reporter assay system (Promega).
Real-time PCR
Total RNA from U2/tetESXR1 cells or U2/tetDC cells was extracted using Trizol Reagent (GIBCO BRL). cDNA generated by SuperScript II reverse transcriptase (Invitrogen) was analysed by PCR using SYBR green PCR kit (Stratagene) and ABI PRISM 7700 Sequence detector (Perkin-Elmer). The copy numbers were normalized with values from human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) measured in separate real-time RT-PCR assays. The PCR amplification was performed using the following K-ras primers: forward, 5 0 -CCAGGTGCGGGAGAGAG-3 0 and reverse, 5 0 -CCCTCA TTGCACTGTACTCC-3 0 .
Electrophoretic mobility shift assay (EMSA)
Cell lysates were prepared from COS-7 cells transfected with WT-ESXR1 expression vector, ESXR1-DC expression vector or control vector as described (Higashi et al., 2002) . DNAbinding reactions were performed on ice in a 20 ml reaction mixture containing 10 mg of total cell lysates, 8 ml of binding buffer (10 mM HEPES, pH 7.5, 60 mM NaCl, 4 mM MgCl 2 , 0.1 mM EDTA, 0.1% NP-40, 10% glycerol), 1 mg of poly(dIdC), 10 mg of bovine serum albumin, and 0.02 pmol of labeled oligonucleotides. For competition assays, 25-or 100-fold molar excess of unlabeled oligonucleotides as competitor was added prior to the binding reaction. For supershift experiments, cell lysates were preincubated with 1 ml of anti-ESXR1 antiserum or normal rabbit IgG (Santa Cruz Biotechnology) for 30 min prior to the binding reaction. DNA-protein complexes were separated by electrophoresis on a 4% polyacrylamide gel in 0.5 Â Tris-borate-EDTA (TBE) buffer at 200 V, and analysed by autoradiography. Double-stranded oligonucleotide probes were labeled by filling in the sticky ends with [a-32 P]dCTP (3000 mCi/mmol, Amersham Biosciences, Piscataway, NJ, USA) and Klenow polymerase (Takara, Shiga, Japan).
Chromatin immunoprecipitation (CHIP)
CHIP was performed using U2/tetESXR1 cells or U2/tetDC cells cultured with DOX for 12 h according to the method described previously (Caretti et al., 2003) . The region between þ 3194 and þ 3442 of the first intron of human K-ras was amplified from the immunoprecipitated chromatin using the following primers: forward, 5 0 -GGGAGTTAAAAGGGTAA AGGACATC-3 0 and reverse, 5 0 -CCCGTTTGCCTCCACG C-3 0 . The 249-bp PCR product was analysed by agarose gel electrophoresis. Anti-TFIIB antibody (Active Motif, Carlsbad, CA, USA) was used as a positive control. Thirty-two cycles of PCR (941C, 20 s; 591C, 30 s and 721C, 30 s) were performed with the use of hot-start method.
